Ovid Therapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $3.69
50-Day Range
MA: $3.85
52-Week Range
Now: $3.69
Volume729,500 shs
Average Volume3.92 million shs
Market Capitalization$242.63 million
P/E RatioN/A
Dividend YieldN/A
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.
Ovid Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OVID
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$1.46 per share


Net Income$-60,460,000.00


Market Cap$242.63 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Ovid Therapeutics Inc. (NASDAQ:OVID) Short Interest Update
March 28, 2021 |
OVID Jul 2021 10.000 call
December 26, 2020 |
OVID Jul 2021 10.000 put
December 26, 2020 |
OVID Jan 2021 5.000 call
December 25, 2020 |
Is OVID A Good Stock To Buy Right Now?
December 16, 2020 |
See More Headlines


Overall MarketRank

1.50 out of 5 stars

Medical Sector

513th out of 2,011 stocks

Pharmaceutical Preparations Industry

247th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

Is Ovid Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ovid Therapeutics stock.
View analyst ratings for Ovid Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Ovid Therapeutics?

Wall Street analysts have given Ovid Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ovid Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,150,000 shares, an increase of 153.1% from the February 28th total of 3,220,000 shares. Based on an average daily trading volume, of 4,150,000 shares, the days-to-cover ratio is presently 2.0 days.
View Ovid Therapeutics' Short Interest

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Ovid Therapeutics

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings data on Sunday, March, 14th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.03.
View Ovid Therapeutics' earnings history

How has Ovid Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OVID stock has increased by 37.7% and is now trading at $3.69.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OVID?

10 brokerages have issued 1 year target prices for Ovid Therapeutics' shares. Their forecasts range from $4.00 to $40.00. On average, they anticipate Ovid Therapeutics' share price to reach $11.63 in the next twelve months. This suggests a possible upside of 215.0% from the stock's current price.
View analysts' price targets for Ovid Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir, Chairman & CEO (Age 68, Pay $821.32k)
  • Dr. Amit Rakhit, Pres & Chief Medical Officer (Age 51, Pay $694.05k)
  • Mr. Timothy G. Daly, Exec. VP of Fin., Treasurer & Corp. Controller (Age 50, Pay $439.45k)
  • Dr. Matthew J. During, Founder & Chairman of Scientific Advisory Board (Age 64)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR
  • Mr. Thomas Michael Perone J.D., M.B.A., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 56)
  • Ms. Suzanne K. Wakamoto SPHR, SHRM-SCP, Sr. VP of HR
  • Dr. Dirk Haasner, Sr. VP of Global Manufacturing & CMC QA (Age 56)
  • Dr. Claude Nicaise, Head of Rare Disease Strategy (Age 68)
  • Mr. Jason Tardio M.B.A., Chief Commercial Officer (Age 44)

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $3.69.

How much money does Ovid Therapeutics make?

Ovid Therapeutics has a market capitalization of $242.63 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics employs 65 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is

Where are Ovid Therapeutics' headquarters?

Ovid Therapeutics is headquartered at 1460 Broadway Suite 15044, New York NY, 10036.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.